To design and advance our clinical programs for the highest potential impact, we have assembled an independent world class Scientific Advisory Board.
Each of the SAB members is a well-known thought leader in the development of new oncology therapeutics, and we view their interest in Actuate Therapeutics’ development programs as strong validation of the potential impact our compounds could have in the clinic.
Chief, Division of Hematology & Oncology, Moores Cancer Center, UCSD
Dr. Razelle Kurzrock is Senior Deputy Director, Clinical Science at Moores Cancer Center at UC San Diego Health, and is also Chief of the Hematology & Oncology Division in the UC San Diego School of Medicine.
Dr. Kurzock is widely known for developing one of the largest and best phase 1 clinical trials programs in the nation while at the University of Texas MD Anderson Cancer Center.
As a physician-scientist, Dr. Kurzrock has demonstrated extraordinary expertise and experience in clinical research, in addition to her world-recognized work in translational science. She has about 450 peer-reviewed publications and a uniquely strong record of competitive grant funding within the setting of phase I program building. She has been the principal investigator of the National Cancer Institute U01 Phase I Studies of Targeted Anti-Cancer Agents.
Professor & Vice Chair, UCLA Department of Neurosurgery; Director, UCLA Brain Tumor Program
Dr. Linda Liau is a neurosurgeon and Professor of Neurosurgery at the David Geffen School of Medicine at UCLA. She is Vice Chair of the UCLA Department of Neurosurgery and Director of the UCLA Brain Tumor Program at the UCLA Medical Center.
Dr. Liau is a full Professor and board-certified neurosurgeon with both an active research laboratory and a busy clinical practice in the field of brain tumors and neurosurgical oncology. Dr. Liau’s clinical expertise is in intra-operative functional brain mapping and use of intra-operative imaging for resection of brain tumors (gliomas, meningiomas, and metastatic tumors). Her research efforts are focused on the molecular biology of brain tumors, gene therapy, immunotherapy, and brain cancer vaccines.
Dr. Liau is the current Editor-in-Chief of the Journal of Neuro-Oncology.
Associate Director of Innovative Medicine, Yale Cancer Center
Before joining the Yale Cancer Center in August 2015, Dr. LoRusso was director of the Phase I Clinical Trials Program and the Eisenberg Center for Experimental Therapeutics at Wayne State University’s Barbara Karmanos Cancer Institute.
Dr. LoRusso has served as co-chair of the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP) Investigational Drug Steering Committee. She also served on the scientific committee of the American Association for Cancer Research (AACR), the education and scientific committees of the American Society of Clinical Oncology (ASCO), numerous peer-reviewed study sections, and NCI committees. She is the current president of Women in Cancer Research and a board member of the American Association for Cancer Research. LoRusso is a former editor of Investigational New Drugs, is currently on the editorial board for Clinical Cancer Research, and is a reviewer for several journals. She has authored more than 200 articles on cancer research in peer-reviewed journals, and written multiple book chapters.
Dr. LoRusso has garnered numerous awards, including the 1999 Heroes of Breast Cancer Award; 2004 Bennett J. Cohen Educational Leadership Award for Medical Research, 2008 NCI Michaele C. Christian Oncology Development Lectureship and Award; the 2014 Targeted Anticancer Therapies (TAT) Honorary Award; and the 2014 Michigan State University Distinguished Alumni Award. She was recently honored as one of the 2014 Massachusetts General Hospital Cancer Center’s “One Hundred” individuals and organizations recognized for their dedication in making a difference in the fight against cancer.
Daniel D. Billadeau, Ph.D. obtained his graduate degree from the University of Minnesota, Mpls, MN in 1996. He did his postdoctoral training with Dr. Paul Leibson at Mayo Clinic in the area of molecular immunology/biochemistry before beginning his independent research career in the Division of Oncology Research at Mayo Clinic in January of 2001. Presently, Dr. Billadeau is Professor and Chair of the Department of Immunology, is Deputy Director for Basic Science in the Mayo Clinic Comprehensive Cancer Center and is the Edmond A. and Marion F. Guggenheim named professor. Dr. Billadeau’s research efforts have focused on identifying molecular targets in pancreatic adenocarcinoma (PDAC), and his group was the first to demonstrate that glycogen synthase kinase-3β is overexpressed and nuclear localized in PDAC and is a viable therapeutic target.